Legend Biotech Reports Strong Q1 2025 Results and Expands CARVYKTI® Reach

The latest update is out from Legend Biotech ( (LEGN) ).

Legend Biotech reported its first quarter 2025 financial results, highlighting strong commercial performance of CARVYKTI® with net trade sales of approximately $369 million and over 6,000 patients treated. The company initiated clinical production at its Tech Lane facility and received regulatory approvals in Europe and Australia, enhancing its market position. Despite a net loss of $100.9 million, Legend Biotech’s collaboration revenue increased significantly, and it maintains a strong cash position of $1.0 billion, providing a financial runway into 2026. The company aims for profitability by next year, driven by manufacturing expansion and global market penetration.

The most recent analyst rating on (LEGN) stock is a Buy with a $80.00 price target. To see the full list of analyst forecasts on Legend Biotech stock, see the LEGN Stock Forecast page.

Spark’s Take on LEGN Stock

According to Spark, TipRanks’ AI Analyst, LEGN is a Neutral.

Legend Biotech’s strong revenue growth and positive earnings call developments are offset by ongoing profitability and cash flow challenges. Technical indicators suggest possible resistance, and valuation remains difficult with negative earnings. The company’s ambitious expansion plans and pipeline developments add potential, but financial stability and operational execution are critical for future success.

To see Spark’s full report on LEGN stock, click here.

More about Legend Biotech

Legend Biotech Corporation is a leading cell therapy company focused on developing innovative treatments for cancer. The company is renowned for its CAR-T cell therapy, particularly CARVYKTI®, which is a treatment for relapsed or refractory multiple myeloma. Legend Biotech collaborates with Johnson & Johnson to develop and market CARVYKTI® and is expanding its operations to enhance patient access and therapeutic potential globally.

Average Trading Volume: 1,354,839

Technical Sentiment Signal: Sell

Current Market Cap: $5.95B

For a thorough assessment of LEGN stock, go to TipRanks’ Stock Analysis page.